(Corrects para 2 to remove reference to ‘link’ between AstraZeneca vaccine and capillary leak syndrome. No such link has been established.)
April 9 (Reuters) - Europe’s drug regulator said on Friday it had started reviewing reports of a bleeding condition in people who had received AstraZeneca’s COVID-19 vaccine and was also looking into Johnson & Johnson’s shot over blood clots.
Four serious cases of rare blood clots with low platelets, one of which was fatal, have been reported after inoculation with J&J’s vaccine from its Janssen unit, the European Medicines Agency said, adding five cases of capillary leak syndrome in people who received AstraZeneca’s vaccine were reported.
Reporting by Pushkala Aripaka in Bengaluru; Editing by Shinjini Ganguli